Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

Make America Healthy Again starts TOMORROW,” joked Donald Trump Jr. in a post on X sharing the picture. While it is hard to ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

In a significant move towards the liberalization of the healthcare sector, Shanghai's Pudong New Area witnessed the first ...

The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...

Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...

We’re joining the National Foundation for Infectious Diseases to raise awareness among U.S. adults, ages 50 and older, about ...